Although the initial response to ponatinib is promising in CML patients with single mutations in BCR-ABL, the response in advanced patients is limited because successive use of TKIs leads to the evolution of compounded BCR-ABL kinase domain mutations that show resistance even to ponatinib [21]. This evidence concerns the gene ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive.